Organoids Services Market Report By Insights, Size, and Growth - 2031

The organoids services market is projected to expand significantly, starting from a valuation of US$ 3.03 billion in 2023 and expected to reach US$ 15.01 billion by 2031. This growth trajectory indicates a compound annual growth rate (CAGR) of 22.3% from 2023 to 2031.

Several factors are driving the growth of the organoids services market, including an increasing demand for innovative drug screening solutions and a surge in the interest for personalized medicine. Nevertheless, challenges such as a shortage of qualified professionals and strict regulatory requirements are hindering market expansion.

Organoids are simplified, tissue-engineered, cell-based in vitro models that mimic various aspects of the complex structure and functionality of their in vivo counterparts. They can be utilized for in-depth mechanistic studies related to development, regeneration, and repair in human tissues. Additionally, organoids serve important roles in diagnostics, disease modeling, drug discovery, and the advancement of personalized medicine.

North America currently leads the organoids services market. Companies in the United States are concentrating on organic growth strategies to enhance their market presence. For instance, in February 2023, Molecular Devices, LLC and HUB Organoids (HUB) announced a strategic partnership aimed at advancing next-generation 3D biology technologies, which are expected to significantly reduce drug attrition rates from preclinical to clinical stages. Furthermore, the rise in research and development initiatives, the growing need for tissue engineering and organ transplantation, along with a high adoption rate of organoids, are propelling the market in this region. Organoids are poised to address many previous limitations in biomedical research, focusing on providing mechanistic insights into human development, creating accurate disease models, and generating patient-specific tissue sources for regenerative medicine. The Asia Pacific region is expected to exhibit the highest CAGR during the period from 2023 to 2031.

Emerging Developments Presenting Future Market Opportunities

The advancement of the healthcare sector has led to an increased global demand for organoids. This demand is fostering new product innovations, acquisitions, partnerships, product launches, and regulatory approvals worldwide. Key players in the market are actively engaged in initiatives to promote the development of effective services and products. Below are some notable recent developments:

? In June 2024, Molecular Devices, LLC inaugurated a state-of-the-art facility in Cardiff, UK. This multimillion-pound facility is designed to support the unique bioprocess workflow and innovative bioreactor technology of the company, enabling large-scale, quality-controlled production of patient-derived organoids (PDOs). These PDOs are available as a custom service and are cryopreserved for immediate analysis, allowing researchers to thaw, plate, and utilize them as required.

? In May 2024, InSphero, a biotechnology firm, entered into a partnership with Genome Biologics in Frankfurt. This collaboration grants InSphero exclusive global rights to commercialize Genome Biologics' 3D Cardiac Organoid Platform, which offers precise, scalable, and disease-specific organoid models for developing new treatments, positioning it at the forefront of heart disease research.

? In July 2023, Molecular Devices expanded its custom organoid line service, incorporating unique bioprocess technology tailored for high-throughput applications.

? In February 2023, Molecular Devices, LLC and HUB Organoids (HUB) announced a strategic collaboration aimed at furthering the development of next-generation 3D biology technologies that significantly reduce drug attrition rates from preclinical to clinical phases.

? In December 2022, Molecular Devices, LLC acquired Cellesce Ltd., focusing on the large-scale production of PDOs for various applications, including drug screening, through contract development and production services.

? In August 2021, STEMCELL Technologies and Hubrecht Organoid Technology (HUB) entered into an agreement whereby STEMCELL's Contract Assay Services division began supplying tissue-derived organoids, such as lung, intestinal, and liver organoids, for preclinical toxicology screening and non-cancer drug development services to HUB. This collaboration aims to facilitate the integration of organoids into preclinical testing programs, thereby accelerating and reducing the costs associated with the launch of new therapies.

These significant developments, product launches, and strategic partnerships among market participants are creating numerous opportunities for growth in the organoid services market.

Insights Based on Applications

The market is categorized by application into developmental biology, infectious disease pathology, regenerative medicine, drug toxicity and efficacy testing, drug discovery and personalized medicine, among others. The developmental biology segment held the largest market share in 2023 and is expected to experience the highest CAGR during the forecast period from 2023 to 2031.

Insights Based on Source

In terms of source, the organoids services market is divided into pluripotent stem cells and organ-specific adult stem cells. The pluripotent stem cells segment accounted for a larger market share in 2023 and is projected to register a higher CAGR throughout the forecast period.

Competitive Landscape and Key Developments in the Organoids Services Market

Key players in the organoids services market include Sino Biological Inc., Eurofins Scientific SE, Molecular Devices, LLC, InSphero, Cyprio, InnoSer, LABTOO, CUSABIO TECHNOLOGY LLC, Oncodesign Services, and HUB Organoids B.V. (Hubrecht Organoid Technology).

The report on the organoids services market references primary and secondary sources, including the US Food and Drug Administration, the Centers for Disease Control and Prevention (CDC), and the Global Burden of Disease Study.